GlaxoSmithKline and partner Theravance are closing in on an important advisory committee meeting for their experimental lung drug Anoro Ellipta next week. And FDA staff has noted in a briefing document that the combination therapy for COPD was effective at two doses, Bloomberg reported.
GlaxoSmithKline is in the middle of a firestorm in China, accused of bribery and potentially facing massive fines from the government. The very public scandal has left a chill on business for it and other drugmakers in this key market. But even with all of that, would the British drugmaker actually pull out of the most populous country in the world, on which it has bet heavily?
GlaxoSmithKline may be on the verge of bidding goodbye to two of its drinks brands. Japan's Suntory Beverage & Food is in advanced talks to buy Lucozade and Ribena, the brands GSK put up for sale early this year, for more than £1 billion ($1.6 billion), Reuters reports.
GlaxoSmithKline experienced a major R&D setback today, reporting that its targeted cancer immunotherapy MAGE-A3 failed its first co-primary endpoint in a Phase III study for melanoma, failing to beat out a placebo in spurring disease-free survival.
It's never good when authorities talk openly of imposing "astronomical" fines on a drugmaker. But China officials have suggested that about GlaxoSmithKline, even as a spray of Chinese news reports accuse former GSK China leader Mark Reilly of fostering a culture that encouraged doing whatever neccessary to hit huge sales goals.
Contrary to GlaxoSmithKline 's official explanations, Chinese police say rogue executives didn't engineer $489 million in alleged bribes. The company itself organized the scheme, they say, and made sure internal auditors didn't uncover it.
The recent, and very public, Chinese investigation into bribery allegations against GlaxoSmithKline and others has doctors running scared, making it tough for everyone to sell drugs there.
A U.S. Centers for Disease Control and Prevention team has found a significant decrease in the number of rotavirus-related hospitalizations with routine use of GlaxoSmithKline ($GSK) and Merck's ($MRK) rotavirus vaccines in older age groups.
One of GlaxoSmithKline's late-stage assets for Crohn's disease has failed a Phase III study, pushing the pharma giant to suspend patient recruitment in the ambitious program. The pharma giant says vercirnon, an inhibitor of the chemokine receptor known as CCR9 in-licensed from ChemoCentryx, flunked the first of four Phase III trials.
China's corruption probe gathered more steam Wednesday with news of the arrest of a British investigator who reportedly worked with pharma companies, including GlaxoSmithKline. It's the latest indication that GSK was just the first target of the investigation, which is sweeping across the industry amid China's attempts to lower healthcare costs.